12 recruiting, 6 completed, 2 not yet recruiting, 1 active not recruiting. 8 Phase 2, 5 Not applicable, 1 Early Phase 1, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Recruiting 7, Active not recruiting 1 |
| Not applicable | 5 | Recruiting 3, Completed 1, Terminated 1 |
| Early Phase 1 | 1 | Not yet recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
| Phase 4 | 1 | Not yet recruiting 1 |
Follow Immune-related Adverse Event: new trials by email Literature Review of Immune-related Adverse Event trials Research Report on Immune-related Adverse Event
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacokinetic Study of Therapeutic Plasma Exchange Spectra Optia Apheresis System - Immune-related Adverse Event | Withdrawn | University of Chicago | 2026-11-01 | 2026-09-24 | ||
| Vedolizumab for the Prevention of ICI Related Diarrhea or Colitis in Patients With Cancer Vedolizumab, Placebo - IrAE, Immune-related Adverse Event | Phase 2 / Phase 3 | Recruiting | AHS Cancer Control Alberta | 36 | 2026-08-13 | 2026-08-27 |
| Mycophenolate Mofetil w/ Prednisone for Immune Related Hepatitis From Checkpoint Inhibitor Therapy Mycophenolate Mofetil plus prednisone - Immune-mediated Hepatitis, Immune-related Adverse Event | Phase 2 | Recruiting | Fox Chase Cancer Center | 31 | 2026-07-23 | 2026-09-17 |
| Inhaled Budesonide for REcurrence Prevention and Adjuvant THerapy in Checkpoint Inhibitor Pneumonitis Arm 2- Budesonide (Pulmicort® Turbuhaler®) + Usual care, Arm 1- Usual care - Pneumonitis, Immune-related Adverse Event | Phase 2 | Recruiting | AHS Cancer Control Alberta | 94 | 2026-02-10 | 2026-08-07 |
| Safety, Virological and Immunological Assessment of the Controlled Dengue Human Infection Model in Dengue-Immune Participants in Thailand (DHIT-Immune) rDEN2Δ30-7169 - Safety Issues, Dengue | Early Phase 1 | Not yet recruiting | Mahidol University | 12 | 2025-09-01 | 2025-04-03 |
| Statins to Prevent Immune Checkpoint Inhibitor-induced PRogression of AtherosLerosis Atorvastatin, Placebo - Atherosclerosis, Melanoma | Phase 4 | Not yet recruiting | Erasmus Medical Center | 140 | 2025-02-01 | 2025-01-22 |
| Exploring the Treatment Duration of PD-1 Neoadjuvant Therapy in Stage II-III dMMR Rectal Cancer Immune-related Adverse Event, Neoadjuvant Therapy | Recruiting | Xijing Hospital | 100 | 2025-01-01 | 2024-12-27 | |
| Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo) Mesalamine - Immune-related Adverse Event, Diarrhea | Phase 2 | Recruiting | AHS Cancer Control Alberta | 20 | 2024-08-20 | 2025-06-27 |
| SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr) Dostarlimab-Gxly 50 MG/1 ML Intravenous Solution [JEMPERLI] - Endometrial Cancer Stage I, Mmr Deficiency | Phase 2 | Recruiting | Queensland Centre for Gynaecological Cancer | 10 | 2024-08-01 | 2024-12-03 |
| The Effect of Serum Ferritin in irAE PD-1 and PD-L1 inhibitor, Targeted drugs, chemotherapy drugs - Immune-related Adverse Event, Malignant Solid Tumors | Not applicable | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 1500 | 2024-07-04 | 2024-11-25 |
| Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis Adalimumab, Prednisone - Inflammatory Arthritis, Immune-related Adverse Event | Phase 2 | Recruiting | Tom Appleton | 30 | 2024-04-15 | 2026-03-03 |
| Hyperpolarized 13C-MRI and Metabolomics for Immune-related Adverse Events Hyperpolarized 13C-MRI - Immune-related Adverse Event | Unknown | Chang Gung Memorial Hospital | 30 | 2024-02-01 | 2024-02-06 | |
| Food Intervention to Reduce Immunotherapy ToXicity Food box containing 30 different plants - Immune-related Adverse Event, Dietary Habits | Not applicable | Recruiting | Universitair Ziekenhuis Brussel | 60 | 2024-01-01 | 2025-03-26 |
| Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced Melanoma Thymosin Alpha 1 and Anti-PD-1 monoclonal antibody - Melanoma, Immune-related Adverse Event | Phase 2 | Recruiting | Sun Yat-sen University | 55 | 2023-05-30 | 2026-06-12 |
| EXploring Immune-related Adverse Events of Immune checkpoinT Inhibitors Using VigiBase, the WHO Pharmacovigilance Database Immune checkpoint inhibitor - Cancer, Immune-related Adverse Event | Completed | Groupe Hospitalier Pitie-Salpetriere | 141630 | 2023-01-01 | 2024-03-05 | |
| Immune-Related Adverse Events and Associated Biomarkers in Patients Receiving Cancer Immunotherapy Medical chart review - Cancer, Immune-related Adverse Event | Completed | Duke University | 30 | 2022-10-05 | 2025-01-28 | |
| Fast-Track Cardiovascular Assessment for Suspicion of Cardiovascular Events on Immunecheckpoint Inhibitors No intervention for research purposes only - Cancer, Immune Checkpoint Inhibitor | Recruiting | Institut Mutualiste Montsouris | 200 | 2022-03-01 | 2023-04-05 | |
| Extensive CArdioVAscular Characterization and Follow-up of Patients Receiving Immune Checkpoint Inhibitors Cardiology consultation, Chest Computed Tomography (CT) without contrast, Non-invasive endothelial function tests - Cancer, Immune-related Adverse Event | Not applicable | Terminated | Algemeen Ziekenhuis Maria Middelares | 105 | 2022-01-07 | 2025-01-30 |
| Treatment of Immune-related Adverse Events Refractory to Standard Therapy and Associated Changes in Immunophenotype Extracorporeal photopheresis, Other immunosuppressive or immunomodulatory drugs - Immune-related Adverse Event | Completed | Lucie Heinzerling | 46 | 2022-01-01 | 2026-09-08 | |
| Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients Undergoing Immune CheckPoint Inhibitors (ICPI) Treatment blood retriewal - Immunotherapy, Immune Checkpoint Inhibitors | Not applicable | Recruiting | Centre Hospitalier Universitaire, Amiens | 150 | 2021-07-02 | 2025-06-04 |
Showing 20 of 24. Sign in to see all of them.
Melanoma (4) · Neoplasms (4) · Arthritis (2) · Atherosclerosis (2) · Colitis (2) · Diarrhea (2) · Carcinoma, Renal Cell (1) · Cardiotoxicity (1) · Colorectal Neoplasms (1) · Dengue (1) · Drug-Related Side Effects and Adverse Reactions (1) · Endometrial Neoplasms (1) · Feeding Behavior (1) · Head and Neck Neoplasms (1) · Myocarditis (1)
Neoplasms (6) · Neoplasms by Site (6) · Neoplasms by Histologic Type (4) · Neoplasms, Germ Cell and Embryonal (4) · Neoplasms, Nerve Tissue (4) · Neuroectodermal Tumors (4) · Neuroendocrine Tumors (4) · Nevi and Melanomas (4) · Pathological Conditions, Signs and Symptoms (4) · Skin Diseases (4) · Skin and Connective Tissue Diseases (4) · Colonic Diseases (3) · Digestive System Diseases (3) · Gastrointestinal Diseases (3) · Intestinal Diseases (3)
Prednisone (3) · Immune Checkpoint Inhibitors (2) · Adalimumab (1) · Adrenal Cortex Hormones (1) · Anti-Inflammatory Agents (1) · Antineoplastic Agents (1) · Antirheumatic Agents (1) · Atorvastatin (1) · Glucocorticoids (1) · Immunomodulating Agents (1) · Infliximab (1) · Mesalamine (1) · Methylprednisolone (1) · Methylprednisolone Hemisuccinate (1) · Mycophenolic Acid (1)
AHS Cancer Control Alberta (3) · Xijing Hospital (2) · Algemeen Ziekenhuis Maria Middelares (1) · Centre Hospitalier Universitaire, Amiens (1) · Chang Gung Memorial Hospital (1) · Diakonhjemmet Hospital (1) · Duke University (1) · Erasmus Medical Center (1) · Fox Chase Cancer Center (1) · Groupe Hospitalier Pitie-Salpetriere (1) · Institut Cancerologie de l'Ouest (1) · Institut Mutualiste Montsouris (1) · Lucie Heinzerling (1) · Mahidol University (1) · Massachusetts General Hospital (1)
Canada (4) · China (4) · France (4) · United States (4) · Belgium (2) · Australia (1) · Germany (1) · Netherlands (1) · Norway (1) · Taiwan (1)
Andreas Obermair, Professor (1) · Brent Hanks, MD PhD (1) · Christof Vulsteke, Prof (1) · Dandan Li, PhD (1) · Jingjing Zhao, PhD (1) · Jipeng Li, Doctor (1) · Jorie Versmissen, MD,PhD (1) · Lucie Heinzerling (1) · Mariana Mirabel, MD, PhD (1) · Marte S Heiberg, MD, PhD (1) · Matthew Zibelman, MD (1) · Michael Dougan, MD, PHD (1) · Nathalie Beaumont (1) · Pankti Reid (1) · Penghui Zhou, PhD (1)
PMID 10741392, PMID 16741252, PMID 20194853, PMID 23045967, PMID 37111382, PMID 39383612, PMID 39955187, PMID 42285609